Anixa Biosciences, Inc.
ANIX · NASDAQ
Market closed$3.40$0.080000 (+2.41%)After hours $3.47 · +2.06%
Key statistics
Previous close$3.32
Open$3.44
Day high$3.55
Day low$3.29
52-week high$5.46
52-week low$2.32
Market cap115.68M
Volume174.51K
Average volume188.64K
P/E ratio-10.97
Forward P/E—
EPS-0.31
Dividend yield0.00%
Market context
Why it moved
ANIX edged higher driven by renewed investor interest in Anixa Biosciences as the stock found technical support near its recent lows and buying momentum built around its oncology pipeline developments.
What is happening
Recent company-specific developments and publisher coverage.
Stock Titan · July 16, 2026Director Lewis Titterton buys more Anixa Biosciences Inc (ANIX) stockPR Newswire · July 14, 2026Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine TechnologyStock Titan · June 29, 2026Anixa gets first Korean patent for breast cancer vaccinePR Newswire · June 26, 2026Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy SymposiumPR Newswire · June 11, 2026Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy SymposiumStock Titan · June 1, 2026Ovarian cancer vaccine targeting 'retired' protein wins Canada patent backingSimply Wall Street · March 25, 2026We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn RatePR Newswire · December 11, 2025Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants Benzinga · July 14, 2026Anixa Biosciences Issued Notice Of Acceptance From IP Australia For Its Breast Cancer Vaccine Technology Mt Newswire · July 6, 2026Anixa Biosciences Treats First Patient in Fifth Cohort of Ovarian Cancer CAR-T Clinical Trial Benzinga · July 6, 2026Anixa Biosciences Doses First Participant In Fifth Group Of Its Phase 1 Clinical Study Of CAR-T/CER-T Therapy For Recurrent Ovarian Cancer Mt Newswire · June 29, 2026Anixa Biosciences Granted Korean Patent for Breast Cancer Vaccine Benzinga · June 29, 2026Anixa Biosciences Receives Patent From South Korea's Ministry Of Intellectual Property For Its Breast Cancer Vaccine Technology Benzinga · June 26, 2026Anixa Biosciences Announces Its Breast Cancer Vaccine's Final Phase 1 Data Shows All Major Primary Endpoints Met, Protocol-Defined Immune Responses Generated In 74% Of Participants Benzinga · June 10, 2026Anixa Biosciences Q2 EPS $(0.07) Beats $(0.09) Estimate Mt Newswire · June 1, 2026Anixa Biosciences Says Canadian IP Office Issues Notice of Allowance for Patent Covering Ovarian Cancer Vaccine Technology